VNDA Share Price

Open 15.85 Change Price %
High 16.50 1 Day 0.30 1.90
Low 15.85 1 Week 2.35 17.09
Close 16.10 1 Month 1.95 13.78
Volume 706665 1 Year 4.75 41.85
52 Week High 18.00
52 Week Low 10.42
VNDA Important Levels
Resistance 2 16.70
Resistance 1 16.45
Pivot 16.15
Support 1 15.75
Support 2 15.50
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.24 -11.11%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
ORCL 50.30 8.57%
ORCL 50.30 8.57%
ORCL 50.30 8.57%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
GCFB 0.95 58.33%
FALC 0.38 52.00%
LOCM 0.09 50.00%
ENOC 7.65 41.67%
TROV 1.30 36.84%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AMRS 3.29 21.40%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
PTSX 0.12 -40.00%
More..

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)

VNDA Technical Analysis 4
As on 22nd Jun 2017 VNDA Share Price closed @ 16.10 and we RECOMMEND Buy for LONG-TERM with Stoploss of 14.68 & Strong Buy for SHORT-TERM with Stoploss of 14.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
VNDA Target for June
1st Target up-side 14.98
2nd Target up-side 15.84
3rd Target up-side 16.7
1st Target down-side 12.52
2nd Target down-side 11.66
3rd Target down-side 10.8
VNDA Other Details
Segment EQ
Market Capital 96253192.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.vandapharmaceuticals.com
VNDA Address
VNDA
2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
United States
Phone: 202-734-3400
Fax: 202-296-1450
VNDA Latest News
Interactive Technical Analysis Chart Vanda Pharmaceuticals Inc. ( VNDA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Vanda Pharmaceuticals Inc.
VNDA Business Profile
Vanda Pharmaceuticals Inc. (Vanda) is a biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of central nervous system disorders. The Company�s product portfolio includes tasimelteon, a compound for the treatment of circadian rhythm sleep disorders (CRSD), which is in clinical development for Non-24, Fanapt, a compound for the treatment of schizophrenia, the oral formulation of which is being marketed and sold in the United States by Novartis Pharma AG (Novartis), and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist.